Table_1_Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era.docx

Table_1_Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era.docx

Background<p>Diffuse large B-cell lymphoma (DLBCL) is an aggressive and the most common type of non-Hodgkin lymphoma (NHL). The clinical use of rituximab has improved the treatment response and survival of patients with DLBCL. The introduction of rituximab biosimilar into healthcare system has...

Full description

Saved in:
Bibliographic Details
Main Author: Reena Nair (11982338) (author)
Other Authors: Gull Mohammad Bhat (17084563) (author), Narendra Agrawal (17084566) (author), Manju Sengar (6834638) (author), Pankaj Malhotra (13885380) (author), Soniya Nityanand (589800) (author), Chitra Lele (17084569) (author), Pramod Reddy (749908) (author), Suresh Kankanwadi (17084572) (author), Narendra Maharaj (17084575) (author)
Published: 2023
Subjects:
Cancer
Cancer Cell Biology
Cancer Diagnosis
Cancer Genetics
Cancer Therapy (excl. Chemotherapy and Radiation Therapy)
Chemotherapy
Haematological Tumours
Molecular Targets
Radiation Therapy
Solid Tumours
Oncology and Carcinogenesis not elsewhere classified
rituximab
real world
DLBCL
biosimilar
Reditux™
Ristova® Rituximab
Ristova®
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items